Chill! For cripe sakes. If you don't have conviction on your investment then what the hell are you doing here.
The nomination to the BoD of Roche employees should allay all concerns.
Indeed. Now will Pharm discovery Co's be interested in using FMI service with a competitor joined at the hip?
Shire has applied to the FDA for dry eye treatment approval. This will be a major headwind for Eleven. The allergic conjunctivitis angle would still be a major plus.
Third Rock, plus a slew of corporate types dumped an average of 78-percent of their holdings. At $50 pps not a bad deal. My suspicion is that we are in purgatory until Roche takes the entire enchilada.
As well as the domestic Pharm. will be contracting FMI for target therapies. The downside is minimal as you pointed out in an earlier post.
Yep. That's how I see it. The other possibilities are that RHBBY decides to ok the 7.7M is not exactly what we wanted but give or take a another 1M we're ok. Or, they go hostile directly to the shareholders to buy the company out.